{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:23:32Z","timestamp":1790177012659,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.clinthera.2014.04.017","type":"journal-article","created":{"date-parts":[[2014,5,17]],"date-time":"2014-05-17T16:15:15Z","timestamp":1400343315000},"page":"967-973","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of Pharmacokinetics of Two Fenofibrate Tablet Formulations in Healthy Human Subjects"],"prefix":"10.1016","volume":"36","author":[{"given":"Siddharth S.","family":"Chachad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Gole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geena","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghu","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.04.017_bib1","unstructured":"World Health Organization. Cardiovascular diseases. Fact sheet N\u00b0317, updated March 2013. http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/. Accessed September 11, 2013."},{"key":"10.1016\/j.clinthera.2014.04.017_bib2","unstructured":"World Health Organization. The World Health Report 2002: reducing risks, promoting healthy life. Geneva, Switzerland: World Health Organization; 2002. http:\/\/www.who.int\/whr\/2002\/en\/. Accessed September 11, 2013."},{"key":"10.1016\/j.clinthera.2014.04.017_bib3","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.04.017_bib4","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0195-668X(03)00347-6","article-title":"European guidelines on cardiovascular disease prevention in clinical practice","volume":"24","author":"De Backer","year":"2003","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2014.04.017_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/21548331.1988.11703636","article-title":"Focus on fenofibrate","volume":"23","author":"Brown","year":"1988","journal-title":"Hosp Pract (Off Ed)"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2014.04.017_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000174541","article-title":"Review of European clinical experience with fenofibrate","volume":"76","author":"Blane","year":"1989","journal-title":"Cardiology"},{"key":"10.1016\/j.clinthera.2014.04.017_bib7","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): a randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.04.017_bib8","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2165\/00003495-200262130-00013","article-title":"Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia","volume":"62","author":"Keating","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2014.04.017_bib9","unstructured":"US Food and Drug Administration. TRICOR\u00ae 48 mg and 145 mg (fenofibrate tablets). Prescribing Information from Abbott Laboratories, USA. Label approved on 02\/05\/2013. http:\/\/www.accessdata.fda.gov. Accessed September 19, 2013."},{"key":"10.1016\/j.clinthera.2014.04.017_bib10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jacl.2008.10.001","article-title":"Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia","volume":"2","author":"Bays","year":"2008","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2014.04.017_bib11","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.numecd.2013.05.002","article-title":"Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update","volume":"23","author":"Reiner","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.clinthera.2014.04.017_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.dsx.2012.09.009","article-title":"Efficacy and safety of statin and fibrate combination therapy in lipid management","volume":"6","author":"Kota","year":"2012","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.clinthera.2014.04.017_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-199834020-00003","article-title":"Clinical pharmacokinetics of fibric acid derivatives (fibrates)","volume":"34","author":"Miller","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2014.04.017_bib14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1345\/aph.1C257","article-title":"Fenofibrate potentiates warfarin effects","volume":"37","author":"Kim","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2014.04.017_bib15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/FJC.0b013e31823de86b","article-title":"The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate","volume":"59","author":"Shen","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2014.04.017_bib16","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jama.2011.353","article-title":"Use of fibrates in the United States and Canada","volume":"305","author":"Jackevicius","year":"2011","journal-title":"JAMA"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181400215X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181400215X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T11:31:36Z","timestamp":1565436696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181400215X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S014929181400215X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.04.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}